Jonathan D Campbell

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. pmc Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature
    David Yamamoto
    Department of Health Systems, Management, and Policy, Colorado School of Public Health, 13001 E 17th Place, Aurora, CO 80045, USA
    Autoimmune Dis 2012:784364. 2012
  2. ncbi request reprint Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis
    Jonathan D Campbell
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO 80045, USA
    Am J Manag Care 19:278-85. 2013
  3. doi request reprint Comparative-effectiveness research to aid population decision making by relating clinical outcomes and quality-adjusted life years
    Jonathan D Campbell
    University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA
    Clin Ther 35:364-70. 2013
  4. ncbi request reprint Increasing pharmaceutical copayments: impact on asthma medication utilization and outcomes
    Jonathan D Campbell
    Universit of Colorado, School of Pharmacy, Aurora, CO 80045, USA
    Am J Manag Care 17:703-10. 2011
  5. pmc Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
    Jonathan D Campbell
    School of Pharmacy, University of Washington, Seattle, USA
    BMC Urol 9:18. 2009
  6. doi request reprint The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective
    J D Campbell
    Department of Clinical Pharmacy, University of Colorado Denver, Aurora, CO, USA
    Allergy 65:1141-8. 2010
  7. ncbi request reprint Managed care opportunities for improving asthma care
    Jonathan D Campbell
    Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, School of Pharmacy, Mail Stop C238, 12850 E Montview Blvd, V20 1205, Aurora, CO 80045, USA
    Am J Manag Care 17:S90-6. 2011
  8. ncbi request reprint Increasing pharmaceutical copayments: impact on asthma medication utilization and outcomes
    Jonathan D Campbell
    University of Colorado School of Pharmacy, Mail Stop C238, Pharmacy and Pharmaceutical Sciences Bldg, 12850 E Montview Blvd, Aurora, CO 80045 E mail
    Am J Manag Care 17:703-10. 2011
  9. ncbi request reprint Association between glycated hemoglobin and health utility for type 1 diabetes
    R Brett McQueen
    Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Mail Stop C238, 12850 E Montview Blvd, Aurora, CO, 80045, USA
    Patient 7:197-205. 2014
  10. doi request reprint Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder
    Jonathan H Watanabe
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Urology 76:835-40. 2010

Detail Information

Publications16

  1. pmc Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature
    David Yamamoto
    Department of Health Systems, Management, and Policy, Colorado School of Public Health, 13001 E 17th Place, Aurora, CO 80045, USA
    Autoimmune Dis 2012:784364. 2012
    ....
  2. ncbi request reprint Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis
    Jonathan D Campbell
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO 80045, USA
    Am J Manag Care 19:278-85. 2013
    ..To estimate the long-term comparative effectiveness of first-line treatment in patients negative for anti-JC virus (JCV) antibodies with glatiramer acetate (GA), fingolimod, or natalizumab for relapsing-remitting multiple sclerosis (RRMS)...
  3. doi request reprint Comparative-effectiveness research to aid population decision making by relating clinical outcomes and quality-adjusted life years
    Jonathan D Campbell
    University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA
    Clin Ther 35:364-70. 2013
    ..Comparative-effectiveness research (CER) at the population level is missing standardized approaches to quantify and weigh interventions in terms of their clinical risks, benefits, and uncertainty...
  4. ncbi request reprint Increasing pharmaceutical copayments: impact on asthma medication utilization and outcomes
    Jonathan D Campbell
    Universit of Colorado, School of Pharmacy, Aurora, CO 80045, USA
    Am J Manag Care 17:703-10. 2011
    ..The objective was to determine the impact of increasing patient prescription copayments for guideline recommended, long-term asthma controller (LTC) medications on asthma-related medication use and healthcare services...
  5. pmc Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
    Jonathan D Campbell
    School of Pharmacy, University of Washington, Seattle, USA
    BMC Urol 9:18. 2009
    ..Our objective was to conduct a literature review and synthesis of published measures of treatment success for OAB with UUI interventions and to identify a treatment success outcome...
  6. doi request reprint The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective
    J D Campbell
    Department of Clinical Pharmacy, University of Colorado Denver, Aurora, CO, USA
    Allergy 65:1141-8. 2010
    ..The study objective was to estimate the costs and consequences of omalizumab compared to usual care from a US payer perspective...
  7. ncbi request reprint Managed care opportunities for improving asthma care
    Jonathan D Campbell
    Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, School of Pharmacy, Mail Stop C238, 12850 E Montview Blvd, V20 1205, Aurora, CO 80045, USA
    Am J Manag Care 17:S90-6. 2011
    ..An optimal managed care plan will adhere to known evidence-based guidelines, can measure outcomes, is targeted to the patient's risk and impairment, and can adapt to changes in our understanding of asthma and its treatment...
  8. ncbi request reprint Increasing pharmaceutical copayments: impact on asthma medication utilization and outcomes
    Jonathan D Campbell
    University of Colorado School of Pharmacy, Mail Stop C238, Pharmacy and Pharmaceutical Sciences Bldg, 12850 E Montview Blvd, Aurora, CO 80045 E mail
    Am J Manag Care 17:703-10. 2011
    ..Conclusions: The findings suggest that even small changes in average copayment for asthma medications can result in significant reductions in medication use and\ unintended increases in healthcare services...
  9. ncbi request reprint Association between glycated hemoglobin and health utility for type 1 diabetes
    R Brett McQueen
    Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Mail Stop C238, 12850 E Montview Blvd, Aurora, CO, 80045, USA
    Patient 7:197-205. 2014
    ..The cross-sectional relationship between HbA1c and health utility scores in adult type 1 diabetes patients was estimated after adjusting for diabetes-related complications...
  10. doi request reprint Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder
    Jonathan H Watanabe
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Urology 76:835-40. 2010
    ....
  11. ncbi request reprint Adherence to statins in primary prevention: yearly adherence changes and outcomes
    Julia F Slejko
    University of Washington School of Pharmacy, Seattle, WA, 98195 7630, USA
    J Manag Care Pharm 20:51-7. 2014
    ..Adherence to statins in real-world practice settings is known to be suboptimal. However, less is known about how adherence changes over time and whether changes in adherence are associated with adverse cardiovascular (CV) outcomes...
  12. doi request reprint Pharmacoeconomics and outcomes research degree-granting PhD programs in the United States
    Julia F Slejko
    Department of Clinical Pharmacy, Center for Pharmaceutical Outcomes Research, University of Colorado Aschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO 80045, USA
    Res Social Adm Pharm 9:108-13. 2013
    ..Evidence is missing on showcasing current practices of degree programs specific to the field of pharmaceutical outcomes research...
  13. doi request reprint Economic differences in direct and indirect costs between people with epilepsy and without epilepsy
    Anne M Libby
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, 12850 E Montview Boulevard, Campus Box C238, Aurora, CO 80045, USA
    Med Care 50:928-33. 2012
    ....
  14. ncbi request reprint Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthma
    Jonathan D Campbell
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington 98195, USA
    Ann Allergy Asthma Immunol 101:474-81. 2008
    ..The National Asthma Education and Prevention Program put forth guidance on how to measure asthma control. This guidance is flexible regarding how the impairment component of control is assessed...
  15. pmc Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes
    R Brett McQueen
    Pharmaceutical Outcomes Research Program, School of Pharmacy, University of Colorado Denver, Aurora, Colorado, USA
    Cost Eff Resour Alloc 9:13. 2011
    ..abstract:..
  16. doi request reprint Economic grand rounds: psychological distress and depression associated with job loss and gain: the social costs of job instability
    Anne M Libby
    School of Pharmacy, University of Colorado Denver, 12631 E 17th Ave, Aurora, CO 80045, USA
    Psychiatr Serv 61:1178-80. 2010
    ..Measurements of the social costs of job instability need to account for costs related to unemployment and underemployment...